产品
编 号：F749325
分子式：C23H22N4O2
分子量：386.45
分子式：C23H22N4O2
分子量：386.45
产品类型
规格
价格
是否有货
1mg
询价
询价
5mg
询价
询价
10mg
询价
询价
结构图
CAS No: 2143072-85-7
产品详情
生物活性：
RAGE 229 is an orally active ctRAGE-DIAPH1 inhibitor. RAGE 229 can inhibit the intracellular RAGE signaling by inhibiting the interaction between the cytoplasmic tail of RAGE(ctRAGE) and Diaphanous-1(DIAPH1).
体内研究：
RAGE229 (oral gavage, 5 mg/kg, twice daily, for 4 days) assuages short- and long-term complications of diabetes in mice. RAGE229 (oral or iv.; 150, 50 and 15 ppm chow; 30, 10, and 3 mg/kg per day per mouse) (5 mg/kg, ip. , every 12 hours for four total doses) reduces plasma concentrations of TNF-α, IL-6, and CCL2/JE-MCP1 in diabetic mice, and reduces pathological and functional indices of diabetes-like kidney disease.Animal Model:female CF-1 mice and male mice with diabetes
Dosage:5 mg/kg
Administration:oral gavage, 5 mg/kg, twice daily, for 4 days
Result:Reduced inflammation score and infarct area in mice.
Animal Model:C57BL/6J mice and BTBR ob/obmice
Dosage:30, 10, and 3 mg/kg; 5 mg/kg
Administration:oral or iv.; 150, 50 and 15 ppm chow; 30, 10, and 3 mg/kg per day per mouse; 5 mg/kg, ip., every 12 hours for four total doses
Result:Reduced the concentrations of CCL2, TNF-α and IL-6.
体外研究：
RAGE229 has affinity for the ctRAGE with KDvalue of 2 nM and inhibits SMC migration with an IC50 value of 26 nM.
RAGE 229 is an orally active ctRAGE-DIAPH1 inhibitor. RAGE 229 can inhibit the intracellular RAGE signaling by inhibiting the interaction between the cytoplasmic tail of RAGE(ctRAGE) and Diaphanous-1(DIAPH1).
体内研究：
RAGE229 (oral gavage, 5 mg/kg, twice daily, for 4 days) assuages short- and long-term complications of diabetes in mice. RAGE229 (oral or iv.; 150, 50 and 15 ppm chow; 30, 10, and 3 mg/kg per day per mouse) (5 mg/kg, ip. , every 12 hours for four total doses) reduces plasma concentrations of TNF-α, IL-6, and CCL2/JE-MCP1 in diabetic mice, and reduces pathological and functional indices of diabetes-like kidney disease.Animal Model:female CF-1 mice and male mice with diabetes
Dosage:5 mg/kg
Administration:oral gavage, 5 mg/kg, twice daily, for 4 days
Result:Reduced inflammation score and infarct area in mice.
Animal Model:C57BL/6J mice and BTBR ob/obmice
Dosage:30, 10, and 3 mg/kg; 5 mg/kg
Administration:oral or iv.; 150, 50 and 15 ppm chow; 30, 10, and 3 mg/kg per day per mouse; 5 mg/kg, ip., every 12 hours for four total doses
Result:Reduced the concentrations of CCL2, TNF-α and IL-6.
体外研究：
RAGE229 has affinity for the ctRAGE with KDvalue of 2 nM and inhibits SMC migration with an IC50 value of 26 nM.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备